Seroprevalence of Human papillomavirus-16, -18, -31, and -45 in a Population-Based Cohort of 10000 Women in Costa Rica

Br J Cancer. 2003 Oct 6;89(7):1248-54. doi: 10.1038/sj.bjc.6601272.

Abstract

Human papillomavirus (HPV) seroprevalence and determinants of seropositivity were assessed in a 10049-woman population-based cohort in Guanacaste, Costa Rica. Serologic responses based on VLP-based ELISA were obtained from the plasma collected at study enrollment in 1993/1994 for HPV-16 (n=9949), HPV-18 (n=9928), HPV-31 (n=9932), and HPV-45 (n=3019). Seropositivity was defined as five standard deviations above the mean optical density obtained for studied virgins (n=573). HPV-16, -18, -31, and -45 seroprevalence was 15, 15, 16, and 11%, respectively. Of women DNA-positive for HPV-16, -18, -31, or -45, seropositivity was 45, 34, 51, and 28%, respectively. Peak HPV seroprevalence occurred a decade after DNA prevalence; lifetime number of sexual partners was the key determinant of seropositivity independent of DNA status and age. DNA- and sero-positive women showed the highest risk for concurrent CIN3/cancer, followed by DNA-positive, sero-negative women.

Publication types

  • Comparative Study
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Viral / blood*
  • Antigens, Viral / immunology
  • Cervical Intraepithelial Neoplasia / epidemiology*
  • Cervical Intraepithelial Neoplasia / virology
  • Cohort Studies
  • Costa Rica / epidemiology
  • DNA, Viral / analysis
  • Female
  • Humans
  • Middle Aged
  • Papillomaviridae / genetics
  • Papillomaviridae / immunology*
  • Papillomavirus Infections / epidemiology*
  • Papillomavirus Infections / virology
  • Polymerase Chain Reaction
  • Seroepidemiologic Studies
  • Uterine Cervical Neoplasms / epidemiology*
  • Uterine Cervical Neoplasms / virology

Substances

  • Antibodies, Viral
  • Antigens, Viral
  • DNA, Viral